Physician profile

Carolyn Dodds Fields

Family Medicine · Greenville, SC

NPI 1144217118

$1,432.72

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $358.42 2019-2020
Janssen Pharmaceuticals, INC $210.36 2019-2020
Astrazeneca Pharmaceuticals LP $185.79 2019-2020
Amgen INC. $85.96 2019
Glaxosmithkline, LLC. $74.16 2019-2020
Lilly USA, LLC $64.01 2019-2020
Astellas Pharma US INC $61.64 2019-2020
Merck Sharp & Dohme LLC $60.45 2019-2020
Sanofi-Aventis U.S. LLC $47.29 2019-2020
Covidien LP $46.25 2019
Pfizer INC. $37.02 2019-2020
Amarin Pharma, INC. $33.09 2020
Boston Scientific Corporation $30.58 2019
Alexion Pharmaceuticals, INC. $18.30 2020
Gilead Sciences, INC. $17.55 2020
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Takeda Pharmaceuticals U.S.A., INC. $14.17 2020
Daiichi Sankyo INC. $14.15 2019
Sanofi Pasteur INC. $14.08 2019
Boehringer Ingelheim Pharmaceuticals, INC. $13.17 2020
Abbvie INC. $12.36 2019
Allergan, INC. $12.21 2019
Teva Pharmaceuticals USA, INC. $10.89 2019
Assertio Therapeutics, INC. $10.82 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Carolyn Dodds Fields

$1,432.72

in general payments reported 2019-2025

Years
2019-2020
Top company
Novo Nordisk INC

https://glasscript.com/doctor/6937/carolyn-dodds-fields

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.